By the end of 2025, more than 16,000 dermatology clinical trials have been completed, ongoing or planned.[1] The number of trials launched has grown significantly over the past decade, peaking in the last year.[1] The Asia-Pacific region saw a nearly fivefold increase in dermatology trials over the previous decade, with a total of nearly 8,000 trials, about the same as North America and Europe combined.[1] Dermatology is one of the fastest growing areas of medicine in terms of trial volume and growth.[1] In one recent phase III trial in plaque psoriasis, 37 centers planned for 508 patients, recruitment was completed six weeks early, even after an 18% increase in subjects.[1] Regulatory authorities increasingly expect more stringent endpoints such as EASI-90/PASI-90 (90% improvement) and IGA 0/1 (clear or nearly clear skin) in dermatology trials.[2] The atopic dermatitis market will exceed $20 billion in 2026, and the psoriasis market will exceed $36 billion.[2] Dermatological researchers must respond flexibly to the rising tide of innovation in this field.[1]